AdvanSix (ASIX, $0.6B mkt cap, two analyst coverage) makes nylon intermediates, ammonium sulfate fertilizer, and acetone at integrated plants in Virginia and Pennsylvania. Q1 2026 results (May 8) confirm what cohort cross-checks across five nitrogen-phosphate peers also show: the Hormuz-driven sulfur supply shock is real, durable, and asymmetric. ASIX is on the wrong side of it. The right side is CF Industries.

What the filing says

Q1 2026 adjusted EBITDA: $5M on $404M sales (+7% YoY). Of the $47M YoY EBITDA decline, $26M is the absence of 2025 insurance proceeds (one-time), $11M is winter storm impact (above the $8-10M guidance), and the balance is higher sulfur, natural gas, and utility costs.

The sulfur escalation is the dominant new data. Q2 2026 quarterly settlement: $655/long ton — up 31% sequential vs Q1's $500, and roughly four times 2025's ≈$165 average. Spot is currently above the Q2 settlement. Q3 settlement "in a couple of months."

ASIX consumes roughly 500K long tons of sulfur annually. The $155/ton sequential jump implies ≈$9M incremental quarterly headwind, ≈$35M annualized vs Q1 run-rate. The Q2 ammonia turnaround recovery (one-time benefit ≈$20-25M pretax) partially offsets, but underlying Q2 EBITDA before turnaround could be near zero or slightly negative. Management's "significant sequential improvement" guidance is the turnaround recovery doing the work, not the operating business.

Management abandoned the Q4 2025 cycle-recovery narrative. CFO Gramm: "pricing probably stays a bit higher for longer... even if there's a resolution in the Middle East, there is quite a bit of time for things to settle back out." The 2008/2022 "precipitous drop" analogies that anchored Q4 2025 commentary are gone.

Pass-through to ammonium sulfate exists but is non-margin-expanding. CEO Kane: "ammonium sulfate pricing actions are largely offsetting sulfur input costs rather than driving margin expansion." The fertilizer year, framed in Q4 2025 with "strong fall fill" optimism, was walked back to "near record but flat vs last year."

Bull levers intact but smaller. The $18M 45Q tax credit (2018-2020 tranche) is confirmed for H2 2026 — IRS field work wrapping Q2. CapEx reaffirmed $75-95M (vs $116M in 2025). A DEF project announced May 7: FID H1 2027, operations 2029, 20%+ IRR.

What the price implies

Forward P/E 8.67x on Street EPS ≈$2.60. Mean analyst target $23.50 (1Y -3.6%). Two coverage: Truist Hold $20, one Buy.

At 8.67x forward on $2.60, the market is pricing partial earnings recovery. It is NOT pricing the asymmetric sulfur cost sensitivity that distinguishes ASIX from cohort, NOR pricing the fertilizer demand walk-back as idio share-loss rather than sectoral softness. Both ASIX-specific bear signals are absent from the multiple.

No insider P-code purchases. Last ten transactions all grants — new CFO Day's $900K (April 27) is forfeited-FMC-equity offset, not conviction.

The cohort bifurcation

The Q1 2026 nitrogen-phosphate cohort confirmed the sulfur shock structurally. Vehicles split by sensitivity:

Cohort duration framing is more bearish than ASIX's own: YARIY's "stranded sulfur," CF's "enduring structural headwind," LXU's nine-plus month call.

Fertilizer demand walk-back is ASIX-idio. NTR maintained CAD 1.75-1.95B retail EBITDA, IPI raised Trio $15/ton, YARIY cited "strong market all nutrients." ASIX is alone walking back. Share or mix loss, not sectoral softness.

Why the gap exists

Two analysts cover ASIX. Sell-side maps ASIX against nylon intermediate comps (LANXESS, BASF), not against ammonium sulfate sulfur dynamics in nitrogen-phosphate peer space. The bifurcation only becomes visible in cross-cohort synthesis across six tickers — the shape isn't pre-built in any single sell-side note. The edge persists until sell-side assembles that synthesis or a Q2 miss forces the re-rating.

Forward EV

Probability-weighted 12-month returns:

ASIX EV is roughly flat — the cohort sympathy rally has already priced any positive bias. CF EV is materially positive against a Street that's already fading the rally (mean target $120.74 vs current $124.48). The cleanest expression of the Hormuz/sulfur factor lives at CF — same factor, opposite sensitivity, EBITDA that actually exists ($983M Q1 vs ASIX $5M). IPI is the second vehicle but tail-risky (UBS $25 target reflects legitimate sulfur-normalization downside; RSI 70.7 today is overbought).

Risks (to the CF long thesis)

1. Hormuz resolution pace — fastest cycle correction collapses the gas spread and urea premium together. CF Q1 beat was 45.7%; that's the upside surprise the market is now pricing — limits the marginal lift.
2. Nitrogen price cycle — urea is already elevated. If Chinese export quotas relax or new capacity ramps, the premium compresses.
3. N. American gas cost trajectory — CF's structural advantage is cheap Henry Hub vs European TTF. Power-driven gas demand for AI datacenters could tighten the basin and erode the moat.
4. CF tape extension — 74% of 52-week range, mean analyst target below current, +50.9% trailing 1Y. Entry on pullback to $115-120 has better Sharpe than chasing today's print rally.

Catalysts

• Jul 31, 2026 — ASIX Q2 earnings. Cost savings program disclosure test; Q2 EBITDA $15-40M (55% probability).
• Aug 5, 2026 — CF Q2 + IPI Q2 same day. Hormuz durability + Trio sustainability test.
• Aug-Sep 2026 — Q3 2026 sulfur quarterly settlement. Dominant variance driver — 62% probability of ≥$655.
• H2 2026 — 45Q $18M ASIX cash receipt — 70% probability by year-end.
• Late Feb 2027 — ASIX 10-K. FY26 FCF >$40M: 52% probability.

What would change our mind (on the CF long)

• Q3 sulfur settlement <$600/ton — cycle reversal invalidates "higher for longer" across the cohort.
• CF Q2 EPS materially missing $5.60 consensus while ASIX surprises positive — cohort bifurcation closing rather than widening.
• Henry Hub / European hub spread tightens 30%+ — CF gas moat erodes.
• Chinese urea export quota relaxation — supply-side pressure on the nitrogen premium.
• 8-K Item 1.01 (ASIX) strategic alternatives — flips ASIX from documented bear leg to event-driven long.

Bottom line

Same factor, opposite signs. CF Q1 EBITDA $983M and ASIX $5M on the identical Hormuz/sulfur dynamic. The market is pricing some of the cohort gap (CF +50.9% 1Y) but not the asymmetry within the factor or the ASIX-idio fertilizer walk-back. CF is where the EV lives; ASIX is the documented bear leg of a sub-factor where the alpha-relevant vehicles sit on the other side. The Q3 sulfur settlement (Aug-Sep) resolves the dominant variance driver — position before, not after.

Evidence